EPI-7386 + abiraterone acetate + prednisone

**EPI-7386 + abiraterone acetate + prednisone** is a combination therapy under clinical investigation for metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC)[1][3][5][7]. EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor that targets the N-terminal domain of the androgen receptor, a site distinct from existing antiandrogens, designed to block androgen receptor transcriptional activity even in the presence of resistance mechanisms such as mutations in the ligand-binding domain[1][9]. Abiraterone acetate is a CYP17 inhibitor, widely approved as a hormonal therapy for prostate cancer, that blocks androgen biosynthesis[1]. Prednisone is included to counteract mineralocorticoid excess due to abiraterone's mechanism. This combination provides dual blockade of androgen receptor signaling: EPI-7386 inhibits AR activity at the N-terminal domain, while abiraterone suppresses androgen production. Prednisone is used to manage side effects related to abiraterone therapy. The combination is primarily investigated in men with mCRPC and mCSPC and is sponsored by ESSA Pharma in collaboration with Janssen[1][3][5][7].

Other names

abirateroneprednisone